Ye Suna, Fang Qiqi, Yao Jinyu, Xing Jianqiang, Tang Shibo, Ma Jacey Hongjie
AIER Eye Hospital, Jinan University, Guangzhou, China.
AIER Eye Institute, Changsha, China.
Front Oncol. 2021 Dec 13;11:773540. doi: 10.3389/fonc.2021.773540. eCollection 2021.
Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel). Her visual acuity did not improve significantly with the cessation of nab-paclitaxel and intravitreal ranibizumab treatment. Then, brinzolamide eye drops were prescribed. One month later, her vision improved, with the macular edema significantly subsided. Finally, we reviewed other cases of CME induced by nab-paclitaxel that have been reported in the literature and discussed the underlying pathogenesis of nab-paclitaxel-induced CME.
血管造影显示隐匿性黄斑囊样水肿（CME）是纳米白蛋白结合型紫杉醇的一种罕见并发症。在此，我们报告一名45岁乳腺癌女性，在接受纳米白蛋白结合型紫杉醇（nab-紫杉醇）治疗数月后发生了CME。停用nab-紫杉醇并给予玻璃体内注射雷珠单抗治疗后，她的视力并未显著改善。随后，开具了布林佐胺滴眼液。一个月后，她的视力有所改善，黄斑水肿明显消退。最后，我们回顾了文献中报道的其他由nab-紫杉醇引起的CME病例，并讨论了nab-紫杉醇诱导CME的潜在发病机制。
